This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moretti, F. Articles by Pontecorvi, A. Search for Related Content PubMed PubMed Citation Articles by Moretti, F. Articles by Pontecorvi, A.

Effects of Exogenous p53 Transduction in Thyroid Tumor Cells with Different p53 Status¹

Molecular Oncogenesis Laboratory, Regina Elena Cancer Institute (F.M., S.N., A.F., M.N., M.C., S.G., A.S., A.P.); Institute of Experimental Medicine, Consiglio Nazionale delle Ricerche (F.M., A.F.); Department of Endocrinology, University La Sapienza (M.N.); Laboratory of Compared Toxicology and Ecotoxicology, ISS (M.C.); and Institute of Medical Pathology, Catholic University (A.P.), 00158 Rome, Italy

Address all correspondence and requests for reprints to: Alfredo Pontecorvi, M.D., Molecular Oncogenesis Laboratory, Regina Elena Cancer Institute and Institute of Medical Pathology, Catholic University, Via delle Messi d’Oro 156, 00158 Rome, Italy.

Recovery of p53 function in undifferentiated thyroid carcinoma cells carrying an altered p53 gene is able to modify cell tumorigenic properties. It is not known whether such an effect may also be achieved in thyroid cancer cells expressing wild-type p53, as in the majority of differentiated thyroid carcinomas. Effects of p53 transduction in a thyroid carcinoma cell line (FRO) exhibiting a wild-type endogenous p53 gene, in comparison to a cell line (WRO) exhibiting mutant p53, were investigated by using an inducible chimeric construct containing human p53 complementary DNA fused to the ligand binding domain of the estrogen receptor (p53ER). FRO cells were unaffected by exogenous p53 expression in terms of both proliferation and viability. On the contrary, p53 reexpression in WRO cells containing hemizygous mutated p53 allele caused a strong growth inhibition due to cell accumulation in the G₁ phase of the cell cycle. In addition, exogenous p53 did not influence FRO cell behavior in response to TSH treatment or modify cell resistance to the chemotherapeutic agent, doxorubicin. Our results indicate that exogenous expression of wild-type p53 affects thyroid tumorigenic properties only in cells carrying an altered p53, whereas it is ineffective in cells expressing wild-type p53 activity. Therefore, the endogenous p53 status seems to be a major determinant for the effectiveness of a p53-based gene therapy for thyroid cancer.

This article has been cited by other articles:

				S. Balthasar, N. Bergelin, C. Lof, M. Vainio, S. Andersson, and K. Tornquist Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells Endocr. Relat. Cancer, June 1, 2008; 15(2): 521 - 534. [Abstract] [Full Text] [PDF]

				C. Ma, A. Kuang, J. Xie, and T. Ma Possible Explanations for Patients with Discordant Findings of Serum Thyroglobulin and 131I Whole-Body Scanning J. Nucl. Med., September 1, 2005; 46(9): 1473 - 1480. [Abstract] [Full Text] [PDF]

				Y. E. Nikiforov Anaplastic Carcinoma of the Thyroid--Will Aurora B Light a Path for Treatment? J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1243 - 1245. [Full Text] [PDF]

				L. J. DeGroot and R. Zhang CLINICAL REVIEW 131: Gene Therapy for Thyroid Cancer: Where Do We Stand? J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 2923 - 2928. [Full Text] [PDF]